Department of Neurology, The Affiliated hospital of Hebei University, Yuhua East Road No. 212, Baoding, 071000, Hebei, China.
Department of Respiratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, China.
BMC Pulm Med. 2018 Nov 20;18(1):171. doi: 10.1186/s12890-018-0734-1.
The purpose of this study was to compare clinical outcomes of Erlotinib versus Gefitinib in the treatment of Asian patients with exon 19 EGFR-mutant lung adenocarcinoma and newly diagnosed brain metastases.
Consecutive Asian patients with exon 19 EGFR-mutant lung adenocarcinoma and newly diagnosed brain metastases were identified and initially received peroral administration of 150 mg/d erlotinib or 250 mg/d gefitinib during 2009-2015. Overall survival (OS) was the primary endpoint. Progression-free survival (PFS) was the second endpoint.
The cohort consisted of 227 Asian patients (erlotinib-treated cohort: n = 112, mean age = 58.5 years [SD: 20.13]; gefitinib-treated cohort: n = 115, mean age = 58.4 years [SD: 19.52]). In a multivariate analysis controlling for age, sex and time span of smoking history, significant difference was detected in the 36-month OS between erlotinib and gefitinib groups (58.3% vs. 49.1%, p = 0.012). There was also significant difference in the 36-month PFS between erlotinib and gefitinib groups (64% vs. 53%, p = 0.013).
For Asian patients with exon 19 EGFR-mutant lung adenocarcinoma and brain metastases, erlotinib was associated with a significantly longer OS and a more prolonged PFS and compared with gefitinib.
本研究旨在比较厄洛替尼与吉非替尼治疗亚洲表皮生长因子受体突变型肺腺癌伴新发脑转移患者的临床结局。
连续纳入 2009 年至 2015 年间接受口服厄洛替尼 150mg/d 或吉非替尼 250mg/d 治疗的亚洲表皮生长因子受体突变型肺腺癌伴新发脑转移患者。总生存期（OS）为主要终点，无进展生存期（PFS）为次要终点。
该队列共纳入 227 例亚洲患者（厄洛替尼治疗组：n=112，平均年龄 58.5 岁[标准差：20.13]；吉非替尼治疗组：n=115，平均年龄 58.4 岁[标准差：19.52]）。多因素分析控制年龄、性别和吸烟史时间跨度后，厄洛替尼组与吉非替尼组的 36 个月 OS 存在显著差异（58.3%比 49.1%，p=0.012）。厄洛替尼组与吉非替尼组的 36 个月 PFS 也存在显著差异（64%比 53%，p=0.013）。
对于亚洲表皮生长因子受体突变型肺腺癌伴脑转移患者，厄洛替尼与吉非替尼相比，OS 更长，PFS 更持久。
